TGen Drug Development Partnership with Imaging Endpoints Provides Comprehensive Clinical Trial Services for Drug Developers
TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced.
“The highest quality medical imaging provided by Imaging Endpoints is one more weapon in TD2’s arsenal,” said Dr. Stephen Gately, president of TD2, which assists drug developers in navigating the regulatory maze involved in the successful completion of clinical trials and bringing new therapeutics to market. “Our relationship is meant to help combine the best available technologies.”
Imaging Endpoints will assist TD2 in the design and implementation of medical imaging analyses. Imaging Endpoints’ expertise in anatomic and functional imaging allows drug developers to best incorporate imaging into their clinical trials: probing molecular drug targets, assessing biologic responses and evaluating drug effectiveness.
“We hope that, through our new relationship with TD2, we will be able to assist oncology drug developers to maximize their return on investment in medical imaging during the course of their early-phase clinical trials,” said Dr. Ron Korn, Medical Director of Imaging Endpoints. “Significant resources and time can be saved through wise and appropriate implementation of medical imaging.”
The rapid completion of often time-consuming and costly clinical trials is needed to speed new treatments to the patients who need them, Dr. Gately said.
Imaging holds the potential to predict outcomes, shorten the time needed to evaluate if a drug is hitting its target, and do so with relatively low risk to patients. By using specific imaging techniques, researchers can assess if new drug compounds are effective in such areas as anti-proliferation, metabolism, and hypoxia.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
